Our client, a world-leading pharmaceutical and diagnostics company, wanted to develop a strategic position in China that would tap into value locally and transfer that value globally.

Our client, a world-leading pharmaceutical and diagnostics company, wanted to develop a strategic position in China that would tap into value locally and transfer that value globally.


The Question:

“What should be our integrated strategy for China to enable global innovation and revenue growth?”

Pharmaceutical industry leaders are increasingly committed to investing and innovating in China. Our client wanted an integrated, sustainable strategy to tap into the Chinese healthcare ecosystem. We helped to them to identify and access emerging opportunities in technology, data, and revenue that would act as global business drivers.

Blue geometric circle website background

Our Answer:

Eradigm worked closely with senior stakeholders across functions and business divisions, contributing to conversations and deliverables at a C-Suite level. The workstream brought together cross-functional colleagues, including R&D, manufacturing, and partnering, to create a unique business proposition. Working client-side as a member of a core working group, we integrated into client teams to inform, facilitate, and expedite work packages. This included the design and implementation of large physical and virtual workshops for colleagues in the EU, US, and China. Eradigm conducted additional research to bring insight to strategic discussions, supporting the development of the final strategy for innovation in China with the core working group.

The Impact:

Because capturing opportunities in China requires bespoke solutions, many Western pharma companies fall into the trap of cutting their China affiliate off from the rest of their organisation. By failing to think globally, they miss the chance to apply their value to other markets. With competitors already committing heavily to strategies in China, this project had to not only make a business case for opportunities in this market; it also had to demonstrate the urgency for timely action. By enabling successful dialogue and collaboration at a C-Suite level, we supported our client with the establishment of an integrated strategy that led to successful implementation and significant investment for the following one-to-five-year period.

Fergus Kennedy

China represents a new frontier for the future of healthcare companies, from pharmaceuticals to digital technologies, representing a unique opportunity to experiment with traditional interests, solutions and business models.

Fergus Kennedy

Senior Consultant